REBECCA WAITE: Open Payments
NPI 1902333065 · VINEYARD, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$971 in 55 payments from 20 companies in 2025. Trend: 2023 $1,031 · 2024 $868 · 2025 $971
Food & beverage: $971
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 19 | $260 |
| AstraZeneca Pharmaceuticals LP | 4 | $67 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $66 |
| Organon LLC | 3 | $61 |
| Corcept Therapeutics | 2 | $53 |
| Lilly USA, LLC | 3 | $50 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $50 |
| PFIZER INC. | 3 | $46 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $43 |
| Novo Nordisk Inc | 2 | $43 |
Products named: VRAYLAR, QULIPTA, CAPLYTA, NEXPLANON, UBRELVY, Korlym, FARXIGA, TRINTELLIX.
Industry payments across UT — which companies pay providers there.
